Contineum Therapeutics’ (CTNM) “Outperform” Rating Reiterated at Royal Bank of Canada
Royal Bank of Canada reissued their outperform rating on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a report published on Thursday morning,Benzinga reports. The firm currently has a $31.00 price target on the stock. CTNM has been the topic of a number of other research reports. Robert W. Baird cut their price objective […]
Royal Bank of Canada reissued their outperform rating on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a report published on Thursday morning,Benzinga reports. The firm currently has a $31.00 price target on the stock. CTNM has been the topic of a number of other research reports. Robert W. Baird cut their price objective […]
